
CLAIMS

~~What is claimed is:~~


1. A compound having the general formula:



, wherein R comprises a linear, saturated alkyl having from 4 to 18 carbons, or a pharmaceutically acceptable salt thereof.


2. The compound of claim 1, wherein R comprises a linear, saturated alkyl having from 11 to 16 carbons.

3. The compound of claim 1, wherein the compound is




, or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1, wherein the compound is



, or a pharmaceutically acceptable salt thereof.


5. The compound of claim 1, wherein the compound is



, or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1, comprising a pharmaceutically acceptable salt, and wherein the salt is one of monohydrate and hyclate.


7. A pharmaceutical composition for preventing metastasis, the composition comprising a compound having the general formula:



, wherein R comprises a linear, saturated alkyl having from 4 to 18 carbons, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.


8. The pharmaceutical composition of claim 7, wherein R comprises a linear, saturated alkyl having from 11 to 16 carbons.

9. The pharmaceutical composition of claim 7, wherein the compound is




, or a pharmaceutically acceptable salt thereof.

10. The pharmaceutical composition of claim 7, wherein the compound is



, or a pharmaceutically acceptable salt thereof.

11. The pharmaceutical composition of claim 7, wherein the compound is



, or a pharmaceutically acceptable salt thereof.

12. The pharmaceutical composition of claim 7, comprising a pharmaceutically acceptable salt, and wherein the salt is one of monohydrate and hyclate.

13. The pharmaceutical composition of claim 7, wherein the pharmaceutically acceptable carrier comprises at least one of a sugar, a starch, cellulose, an excipient, an oil, a glycol, a polyol, an ester, an agar, and a buffering agent.

14. ~~The~~Use of the pharmaceutical composition of any of claims 7-13~~, for use in one of~~ in the manufacture of a medicament for preventing metastasis, reducing inflammation, reducing fibrosis, and/or reducing viral replication.

~~15. A method for preventing metastasis in a patient, the method comprising administering to the patient a pharmaceutically effective amount of a pharmaceutical composition of any of claims 7-13.~~

~~16. A method for reducing inflammation in a patient, the method comprising administering to the patient a pharmaceutically effective amount of a pharmaceutical composition of any of claims 7-13.~~

~~17. A method for reducing fibrosis in a patient, the method comprising administering to the patient a pharmaceutically effective amount of a pharmaceutical composition of any of claims 7-13.~~

~~18. A method for reducing virus replication in a patient, the method comprising administering to the patient a pharmaceutically effective amount of a pharmaceutical composition of any of claims 7-13.~~